Stockreport

Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

Cardiff Oncology, Inc.  (CRDF) 
PDF Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs [Read more]